Aethlon Medical (AEMD) Price & Analysis

Compare

590 Followers

AEMD Stock Chart & Stats

$3.70

-$0.16(-18.80%)

At close: Jan 08 4:00 PM EST

$3.70

-$0.16(-18.80%)

Day’s Range― - ―

52-Week Range$3.42 - $84.40

Previous CloseN/A

Volume1.62M

Average Volume (3M)688.41K

Market Cap

$3.44M

Enterprise Value-$586.88K

Total Cash (Recent Filing)$5.85B

Total Debt (Recent Filing)$496.77M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Feb 16, 2026

EPS Estimate

-2.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.74

Shares Outstanding761,211

10 Day Avg. Volume703,784

30 Day Avg. Volume688,413

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.87

Price to Sales (P/S)0.00

P/FCF Ratio-0.58

Enterprise Value/Market Cap-0.17

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.50

Enterprise Value/Ebitda0.05

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe first cohort of three patients in the Australian Hemopurifier cancer trial were treated without device-related serious adverse events, and the Data Safety Monitoring Board recommended advancing to the second treatment cohort.

Cost ControlOperating expenses of $1.5M were down 48.0% year-over-year, underscoring the company’s commitment to cost control.

Financial ManagementAEMD continues to manage its financial position responsibly by keeping operating expenses stable and narrowing its focus to high-potential programs.

Bears Say

Commercialization UncertaintyDespite cost control efforts, capital limitations and clinical uncertainty continue to limit visibility on a commercialization timeline.

Revenue ForecastAEMD reported no revenue during the quarter, and no revenue recognition is forecasted in FY26 or FY27.

Technology ValidationAEMD continues to make incremental progress across its clinical and regulatory programs, but extensive further testing is required to validate the technology.

Aethlon Medical News

Aethlon Medical’s Hemopurifier shows potential efficacy in long COVID

Aethlon Medical (AEMD) announced the 20 November 2025 publication of a pre-clinical study in the pre-print online archive...

2d ago

AEMD

Aethlon Medical reports Q2 EPS ($3.74) vs. ($16.11) last year

As of September 30, 2025, Aethlon had a cash balance of approximately $5.8M. “We remain focused on executing...

22d ago

AEMD

Aethlon Medical’s Earnings Call: Progress Amid Challenges

Aethlon (($AEMD)) has held its Q2 earnings call. Read on for the main highlights of the call. The...

21d ago

AEMD

Aethlon Medical Reports Q2 2025 Financial Results

Aethlon ( ($AEMD) ) has released its Q2 earnings. Here is a breakdown of the information Aethlon presented...

22d ago

AEMD

Aethlon Medical Reports Q2 Financial Results and Progress

Aethlon Medical ( ($AEMD) ) has provided an update. On November 12, 2025, Aethlon Medical announced its financial...

22d ago

AEMD

Aethlon Medical Regains Nasdaq Compliance After Stock Surge

Aethlon Medical ( ($AEMD) ) has issued an announcement. On November 5, 2025, Aethlon Medical, Inc. announced it...

28d ago

AEMD

Aethlon Medical Faces Nasdaq Non-Compliance Notice

Aethlon Medical ( ($AEMD) ) has provided an update. On October 16, 2025, Aethlon Medical received a notification...

1M ago

AEMD

Upcoming Stock Splits This Week (October 20 to October 24) – Stay Invested

These are the upcoming stock splits for the week of October 20 to October 24, based on TipRanks’ Stock...

2M ago

WOK

AEMD

Aethlon Medical trading halted, news pending

19:50 EDT Aethlon Medical (AEMD) trading halted, news pending Published first on TheFly – the ultimate source for...

2M ago

AEMD

Aethlon Medical Announces Reverse Stock Split

Aethlon Medical ( ($AEMD) ) just unveiled an update. On October 14, 2025, Aethlon Medical, Inc. filed a...

2M ago

AEMD

Aethlon Medical Announces New Share Structure Update

Aethlon Medical ( ($AEMD) ) has provided an update. On September 12, 2025, Aethlon Medical, Inc. announced that...

3M ago

AEMD

Aethlon Medical Completes $4.5 Million Public Offering

Aethlon Medical ( ($AEMD) ) has shared an announcement. On September 4, 2025, Aethlon Medical, Inc. entered into...

3M ago

AEMD

Aethlon Medical announces pricing of $4.5M common stock, warrant offering

Aethlon Medical (AEMD) announced the pricing of a public offering of an aggregate of 5M shares of its...

3M ago

AEMD

Aethlon Medical announces issuance of patents protecting Hemopurifier

Aethlon Medical (AEMD) announced that U.S. Patent No. 12,409,260 directed to treatment of Long COVID will issue on...

3M ago

AEMD

AEMD FAQ

What was Aethlon Medical Inc’s price range in the past 12 months?

Aethlon Medical Inc lowest stock price was $3.42 and its highest was $84.40 in the past 12 months.

What is Aethlon Medical Inc’s market cap?

Aethlon Medical Inc’s market cap is $3.44M.

When is Aethlon Medical Inc’s upcoming earnings report date?

Aethlon Medical Inc’s upcoming earnings report date is Feb 16, 2026 which is in 73 days.

How were Aethlon Medical Inc’s earnings last quarter?

Aethlon Medical Inc released its earnings results on Nov 12, 2025. The company reported -$3.74 earnings per share for the quarter, missing the consensus estimate of -$3.663 by -$0.077.

Is Aethlon Medical Inc overvalued?

According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aethlon Medical Inc pay dividends?

Aethlon Medical Inc does not currently pay dividends.

What is Aethlon Medical Inc’s EPS estimate?

Aethlon Medical Inc’s EPS estimate is -2.61.

How many shares outstanding does Aethlon Medical Inc have?

Aethlon Medical Inc has 761,211 shares outstanding.

What happened to Aethlon Medical Inc’s price movement after its last earnings report?

Aethlon Medical Inc reported an EPS of -$3.74 in its last earnings report, missing expectations of -$3.663. Following the earnings report the stock price went up 12.857%.

Which hedge fund is a major shareholder of Aethlon Medical Inc?

Currently, no hedge funds are holding shares in AEMD

Company Description

Aethlon Medical Inc

Aethlon Medical, Inc. (AEMD) is a biotechnology company focused on developing innovative therapies for life-threatening diseases. The company primarily operates in the healthcare sector, offering medical devices and therapeutic solutions aimed at addressing unmet medical needs, particularly in the areas of oncology and infectious diseases. Aethlon's flagship product, the Hemopurifier, is a first-in-class device designed to selectively filter and remove harmful viruses and exosomes from the bloodstream, which can contribute to disease progression and immune suppression.

Aethlon Medical (AEMD) Earnings & Revenues

Historic Earnings Reports

AEMD Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in clinical trials and substantial reduction in operating expenses, indicating effective cost management. Nonetheless, challenges in patient recruitment for the oncology trial and concerns about cash reserves present potential hurdles. The company's strategic focus on its core projects while managing resources optimally reflects a balanced approach.View all AEMD earnings summaries

AEMD Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"140":"$140","-1":"-$1","34.25":"$34.3","69.5":"$69.5","104.75":"$104.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,34.25,69.5,104.75,140],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.26,4.855384615384615,4.450769230769231,4.046153846153846,3.6415384615384614,3.236923076923077,2.832307692307692,2.4276923076923076,2.023076923076923,1.6184615384615384,1.2138461538461538,0.8092307692307692,0.4046153846153846,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.26,4.855384615384615,4.450769230769231,4.046153846153846,3.6415384615384614,3.236923076923077,2.832307692307692,2.4276923076923076,2.023076923076923,1.6184615384615384,1.2138461538461538,0.8092307692307692,0.4046153846153846,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.26,4.855384615384615,4.450769230769231,4.046153846153846,3.6415384615384614,3.236923076923077,2.832307692307692,2.4276923076923076,2.023076923076923,1.6184615384615384,1.2138461538461538,0.8092307692307692,0.4046153846153846,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":139.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.56,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.769,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.294,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":68.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":55.991,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.416,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.463,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.759,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.799,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.599,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >